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We investigated an outbreak of Acinetobacter baumannii in an intensive care unit and in the surgery, med-
icine, neurology, and urology wards of the Kosin University Gospel Hospital in Busan, Korea. The outbreak
involved 36 cases of infection by A. baumannii producing the OXA-23 -lactamase over an 8-month period and
was caused by a single pulsed-field gel electrophoresis clone. The epidemic isolates were characterized by a
modified cloverleaf synergy test. Isoelectric focusing of crude bacterial extracts detected one nitrocefin-positive
band with a pI value of 6.65. PCR amplification and characterization of the amplicons by direct sequencing
indicated that the epidemic isolates carried a blaOXA-23 determinant. The epidemic isolates were characterized
by a multidrug resistance phenotype that remained unchanged over the outbreak, including penicillins, cepha-
mycins, extended-spectrum cephalosporins, carbapenems, monobactams, and aminoglycosides. This study
shows that the blaOXA-23 resistance determinant may become an emerging therapeutic problem.
Acinetobacter baumannii has emerged as an important nos-
ocomial pathogen in outbreaks of hospital infections and is
ranked second after Pseudomonas aeruginosa among noso-
comial pathogens of aerobic nonfermentative gram-negative
bacilli (17, 19). A. baumannii causes respiratory and urinary
tract infections, meningitis, endocarditis, burn infections, and
wound sepsis, especially in intensive care units (ICUs) (4).
A. baumannii infections are often difficult to eradicate due to
high-level resistance to many antibiotics as a result of both
intrinsic and acquired mechanisms. -Lactamase production is
the most important mechanism of acquired -lactam resistance
in gram-negative pathogens (21). Carbapenems (e.g., imipen-
em and meropenem) have become the drugs of choice against
Acinetobacter infections in many centers but are being com-
promised by the emergence of carbapenem-hydrolyzing -lac-
tamase (carbapenemase) of molecular classes B and D (14).
Class B carbapenemases found thus far in Acinetobacter spp.
include various IMP- and VIM-type metallo--lactamases (http:
//www.lahey.org/studies/webt.asp), but most Acinetobacter spp.
produce zinc-independent members of -lactamase molecular
class D (1). Sequenced carbapenemases of this latter class from
that species include the following two distinct clusters: (i) the
OXA-23-like cluster (OXA-23 and -27) and (ii) the OXA-24-
like cluster (OXA-24, -25, -26, and -40). OXA-23 and OXA-27
have 99% amino acid identity, whereas they have only 60%
identity with those of OXA-24-like cluster (1, 3, 6, 7).
Over an 8-month period from January to August 2003, 193
A. baumannii isolates were isolated from 193 patients hospi-
talized at the Kosin University Gospel Hospital. The purpose
of the present study was to investigate an outbreak of A. bau-
mannii in Korea and to characterize the imipenem resistance
mechanism of the outbreak isolates.
MATERIALS AND METHODS
Bacterial strains and susceptibility tests. A total of 193 nonrepetitive clinical
isolates of A. baumannii were isolated from January to August 2003 in the Kosin
University Gospel Hospital (Busan, Republic of Korea) with 1,300 beds. These
isolates were collected from different patients hospitalized at ICUs and in sur-
gery, medicine, neurology, and urology wards. The isolates were identified by
using conventional techniques (17) and/or Vitek GNI card (bioMe´rieux Vitek,
Inc., Hazelwood, Mo.). A. baumannii (YMC02/8/P535) (21) was used as the
recipient strain for transfer by transconjugation. Escherichia coli DH5 and
E. coli ATCC 25922 were used as the host strain for transformation and the MIC
reference strain, respectively.
Antibiotic susceptibility was determined by disk diffusion tests that were per-
formed according to the manufacturer’s instructions with BBL (Cockeysville,
Md.) disks impregnated with amikacin (30 g), ciprofloxacin (5 g), gentamicin
(10 g), tetracycline (30 g), tobramycin (10 g), trimethoprim-sulfamethox-
azole (1.25 and 23.75 g, respectively), ampicillin (10 g), ampicillin-sulbactam
(10 and 10 g, respectively), piperacillin (100 g), piperacillin-tazobactam (100
and 10 g, respectively), cephalothin (30 g), cefoxitin (30 g), cefoperazone
(75 g), ceftazidime (30 g), cefotaxime (30 g), cefepime (30 g), aztreonam
(30 g), and imipenem (10 g). Disks were dispensed with a BBL Sensi-Disk
12-place dispenser. MICs were determined by the agar dilution technique on
Muller-Hinton agar plates (Becton-Dickinson, Sparks, Md.) containing serially
twofold-diluted -lactams as described previously (15).
Microbiological tests of carbapenemase activity. In order to study the inacti-
vation of imipenem by the A. baumannii OXA-type -lactamase, a microbiolog-
ical disk synergy test was performed. The cloverleaf test of Hornstein et al. (8)
was modified by substituting E. coli ATCC 25922 for imipenem-susceptible
Micrococcus luteus and using Acinetobacter genomospecies 3 YMC 99/11/160 as
a VIM-2-producing positive control. The surface of a Muller-Hinton agar plate
was inoculated evenly by using a cotton swap with an overnight culture suspen-
sion of E. coli, which was adjusted to the turbidity of the McFarland no. 0.5 tube.
After brief drying, an imipenem disk was placed at the center of the plate, and
imipenem-resistant test strains from the overnight culture plates were streaked
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heavily from the edge of the disk to the periphery of the plate. The presence of
a distorted inhibition zone after overnight incubation was interpreted as a pos-
itive modified cloverleaf synergy test showing the inactivation of imipenem by
carbapenemase (class B and/or D).
Microbiological testing of metallo--lactamase activity was performed with an
EDTA-disk test synergy test (11) modified as follows. An overnight culture of the
test strain was suspended to the turbidity of the McFarland no. 0.5 tube and used
to swab inoculate a Muller-Hinton agar plate. After drying, a 30-g imipenem
disk (BBL) and a blank filter paper disk were placed 15 mm apart from edge to
edge, and 10 l of 0.5 M EDTA solution was then applied to the blank disk,
which resulted in ca. 1.5 mg/disk. After overnight incubation, the presence of
enlarged zone of inhibition was interpreted as EDTA-disk synergy test positive
showing the inactivation of metallo--lactamase (class B) activity by EDTA.
Transconjugation experiments and IEF analysis. Curing was attempted by
growing cultures overnight in nutrient broth containing ethidium bromide (Sig-
ma-Aldrich, Louis, Mo.) at 0.25 to 0.5 times the MIC, followed by replica plating
on to Muller-Hinton agar plates with or without imipenem at 2 or 10 mg/liter.
Isolation of plasmid DNA was performed as described by Sambrook and Russell
(16) with plasmid-safe ATP-dependent DNase (Epicentre Technology, Madison,
Wis.) for removing contaminated bacterial chromosomal DNA. Transconjuga-
tion experiments were performed as described previously (21) with rifampin-
resistant A. baumannii (YMC02/8/P535) as the recipient. Transconjugants were
selected on Muller-Hinton agar supplemented with rifampin (100 mg/liter) to
inhibit the growth of the donor strain and with imipenem (1 mg/liter) to inhibit
the growth of the recipient strain. Crude bacterial extracts were obtained from
clinical isolates after centrifugation of sonicated culture as previously described
(12). Sonic extracts were used for the determination of isoelectric points (pIs)
and -lactamase activity. Isoelectric focusing (IEF) was performed in Ready Gel
precast IEF polyacrylamide gels (Bio-Rad, Hercules, Calif.) as previously de-
scribed (12). Gels were developed with 0.5 mM nitrocefin (Merck, Whitehouse
Station, N.J.).
Molecular studies. Unless otherwise stated, molecular biological reagents and
restriction enzymes were obtained from Sigma-Aldrich. Genomic DNA of clin-
ical isolates were prepared with Wizard Genomic DNA Purification Kit (Pro-
mega, Madison, Wis.) and used as template DNA in PCR. The primers for PCR
amplification were designed by selecting consensus sequences in multiple-nucle-
otide alignment of six OXA-type -lactamase genes (blaOXA), five IMP-type
-lactamase genes (blaIMP), and six VIM-type -lactamase genes (blaVIM) by us-
ing the Primer3 program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www
.cgi). The primers are described in Table 1. PCR amplifications were carried out
as described previously (9, 10). For the cloning of blaOXA-23 gene, the PCR
products were cloned into pGEM-T (Promega), and the recombinant plasmids
were transformed into chemically competent cell of E. coli DH5 by heat shock
as detailed in the supplier’s instructions. Transformants were selected and sub-
cultured on nutrient agar plates containing ampicillin (100 mg/liter).
DNA sequencing was performed by the direct sequencing method with an
automatic sequencer (ABI Prism3100; Applied Biosystems, Weiterstadt, Ger-
many) as previously described (13). DNA sequence analysis was performed with
DNASIS for Windows (Hitachi Software Engineering America, Ltd., San Bruno,
Calif.). Database similarity searches for both the nucleotide sequences and
deduced protein sequences were performed with BLAST at the National Center
for Biotechnology Information website (http://www.ncbi.nlm.nih.gov).
For pulsed-field gel electrophoresis (PFGE), SmaI-digested genomic DNA
was prepared according to the instruction of Bio-Rad (Hercules, Calif.), and
fragments were separated for 20 h at 6 V/cm at 11°C by using a CHEF-DRII
system (Bio-Rad), with initial and final pulse times of 0.5 and 60 s, respectively.
DNA fingerprints were interpreted as recommended by Tenover et al. (20)
Transfer of SmaI-digested genomic DNA to nylon membrane (Hybond-N;
Amersham International, Buckinghamshire, England) was performed essentially
as described by Sambrook and Russell (16). Labeling of DNA (PCR product
between OXA-23F primer and OXA-23R primer) probe was performed with
digoxigenin as described by the manufacturer (Roche Diagnostics GmbH, Mann-
heim, Germany). Southern hybridization was performed at 68°C with the buffers
recommended in the instructions included in the digoxigenin kit from Roche.
RESULTS
Phenotypic properties of imipenem-resistant isolates. The
results of antimicrobial susceptibility testing of 193 nonre-
petitive A. baumannii isolates showed a significant detection
(26.9%, 52 of 193) of imipenem-resistant isolates. A total of 52
isolates of imipenem-resistant A. baumannii were studied by
using the modified cloverleaf synergy test and the EDTA-disk
FIG. 1. Modified cloverleaf test results for a representative OXA-
23-producing isolate (A. baumannii K10708) (A), a VIM-2-producing
positive control (A. genomospecies 3 YMC 99/11/160) (B), and a
non-OXA-23-producing strain (A. baumannii ATCC 19606) (C). A
Mueller-Hinton agar plate was incubated with E. coli ATCC 25922. An
imipenem disk was put in the center, and test isolates were streaked
from the edge of the disk to the periphery of the plate, followed by
overnight incubation.
TABLE 1. Nucleotide sequences of oligonucleotides used for PCR amplifications and sequencing of blaOXA-23-like,
blaOXA-24-like, blaIMP-type, and blaVIM-type genes
Primer (orientation)a Accession no. of blab Sequence (533) Annealing sitec Amplicon size (bp)d
OXA-23F (F) AJ132105 GATGTGTCATAGTATTCGTCGT 108 to 87 1,058
OXA-23R (R) AF201828 TCACAACAACTAAAAGCACTGT 929 to 950 (OXA-23F/-23R)
OXA-24F (F) AJ239129, AF201826 ATGAAAAAATTTATACTTCCTATATTCAGC 1 to 30 825
OXA-24R (R) AF201827, AF509241 TTAAATGATTCCAAGATTTTCTAGC 801 to 825 (OXA-24F/-24R)
IMP-F (F) S71931, AB010417, AF290912 CATGGTTTGGTGGTTCTTGT 154 to 173 488
IMP-R (R) AB040994, AB074433 ATAATTTGGCGGACTTTGGC 582 to 601 (IMP-1F/-1R)
VIM-F (F) AF191564, AF300454, AY165025 ATTGGTCTATTTGACCGCGTC 24 to 44 780
VIM-R (R) AY524987, AY524988, AY524989 TGCTACTCAACGACTGAGCG 784 to 803 (VIM-2F/-2R)
a Orientation of each primer: F, forward; R, reverse.
b -lactamase genes (bla) used in the multiple sequence alignment for designing each primer pair.
c Positions of annealing sites are with respect to the first nucleotide of the coding region (1).
d The primer pair for PCR amplification is indicated in parentheses.
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synergy test. Metallo--lactamase-producing isolates (EDTA-
disk synergy test positive) were not detected. The prevalence of
carbapenemase-producing isolates (modified cloverleaf syn-
ergy test positive) was 69.2% (36 of 52) (Fig. 1 and Table 2).
These results were confirmed with the carbarpenemase activity
data by spectrophotometric assays in the presence or absence
of EDTA. The results suggest that 36 imipenem-resistant
A. baumannii isolates do not produce class B metallo--lacta-
mases but produce other type -lactamases. Thirty-six -lacta-
mase-producing A. baumannii were isolated from 36 different
patients hospitalized in nine wards (cardiac internal medicine,
cardiac surgery, general surgery, kidney internal medicine, neu-
rology, neurosurgery, orthopedic surgery, pulmonary internal
medicine, and urology) and showed high levels of resistance to
amikacin, gentamicin, tetracycline, tobramycin, ampicillin, piper-
acillin, piperacillin-tazobactam, cephalothin, cefoxitin, cefopera-
zone, ceftazidime, cefotaxime, cefepime, aztreonam, and imipen-
em (Table 2). Eight -lactamase-producing A. baumannii isolates
were only sensitive to ampicillin-sulbactam of the antibiotics
tested (22.2%, 8 of 36). All 36 clinical isolates and their trans-
formants produced a -lactamase with an apparent pI of 6.65
(data not shown). Based on IEF results and on the previous
reports of OXA-23-producing A. baumannii (6) and Proteus
mirabilis (2), we suspected that the OXA-23 carbapenemase
(class D) could be involved in imipenem resistance.
Molecular characterization of OXA-23-producing A. bau-
mannii isolates. Neither transfer nor curing of imipenem re-
sistance was achieved for any imipenem-resistant isolate, de-
spite multiple attempts. blaOXA-carrying plasmid DNA was
apparently not detectable either in plasmid preparation with-
out contaminated bacterial chromosomal DNA by plasmid-
safe ATP-dependent DNase or in whole genomic DNA prep-
arations from 36 isolates. In a Southern blot experiment
carried out with the genomic DNA of 36 isolates, the blaOXA-23
TABLE 2. Characterization of imipenem-resistant A. baumannii isolates harboring the blaOXA-23 gene
Isolate Datea of isolation Wardb Isolate sourcec Isolate resistance, non--lactamsd
Synergy test
Clover leaf EDTA disk
K10708 16/1/2003 NE E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K11468 30/1/2003 NE E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K12817 28/2/2003 NE E-tube Amik, Cpfx, Gm, Tet, Tm  
K13710 15/3/2003 GS E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K13994 20/3/2003 PI E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K14190 25/3/2003 UR Pus Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K14249 27/3/2003 NS Urine Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K14615 3/4/2003 CS E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K14910 10/4/2003 CS Sputum Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K14911 11/4/2003 NS Sputum Amik, Cpfx, Gm, Tet, Tm  
K15034 13/4/2003 KI Sputum Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K15289 17/4/2003 PI Sputum Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K15348 18/4/2003 NS E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K15657 25/4/2003 NE E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K15929 1/5/2003 NS Sputum Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K14687 4/4/2003 GS Wound Amik, Gm, Tet, Tm, Tp/Sx  
K16386 19/5/2003 OS Wound Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K18031 9/6/2003 NS E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K17885 10/6/2003 PI SCVP tip Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K17877 8/6/2003 NE E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K18909 26/6/2003 NS Urine Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K19654 11/7/2003 NE E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K19706 12/7/2003 NE Sputum Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K20180 21/7/2003 NS IV catheter Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K15173 14/4/2003 GS Wound Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K15382 18/4/2003 PI Sputum Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K15647 24/4/2003 GS Wound Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K21090 4/8/2003 CS E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K21161 5/8/2003 OS Wound Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K21115 6/8/2003 NE E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K21312 7/8/2003 NS Urine Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K21503 13/8/2003 NS Urine Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K21846 20/8/2003 CI Sputum Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K22202 27/8/2003 NS Sputum Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K22222 27/8/2003 NS E-tube Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
K16544 15/5/2003 NS Sputum Amik, Cpfx, Gm, Tet, Tm, Tp/Sx  
YMCe  
19606f  
a Dates are presented as day/month/year.
b CI, cardiac internal medicine; CS, cardiac surgery; GS, general surgery; KI, kidney internal medicine; NE, neurology; NS, neurosurgery; OS, orthopedic surgery;
PI, pulmonary internal medicine; UR, urology.
c E-tube, endotracheal tube; IV, intravenous; SCVP, subclavian vein catheter.
d Amik, amikacin; Cpfx, ciprofloxacin; Gm, gentamicin; Tet, tetracycline; Tm, tobramycin; Tp/Sx, trimethoprim-sulfamethoxazole (1:19).
e Imipenem-sensitive A. baumannii ATCC 19606.
f VIM-2-producing A. genomospecies 3 YMC 99/11/160.
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probe hybridized to the band of chromosomal DNA. Thirty-six
clinical isolates gave a PCR product with the OXA-23F/OXA-
23R primer pair but not with other primer pairs (OXA-24F/
OXA-24R, IMP-F/IMP-R, and VIM-F/VIM-R). A 1,058-bp
PCR product (between OXA-23F and OXA-23R primer) for
blaOXA-23-like cluster genes was obtained. Taking into account
the resistance phenotypes of 36 clinical isolates, the resistance
genotypes of these isolates were analyzed by direct sequencing
of the PCR-amplified fragments specific for blaOXA-23-like
cluster genes. On the basis of DNA sequencing, 36 clinical
isolates and their transformants were determined to harbor the
blaOXA-23 gene. The OXA-23 carbapenemase was involved in
the imipenem resistance as previously described (5, 6).
PFGE analysis. SmaI macrorestriction analysis was con-
ducted on 36 OXA-23-producing isolates obtained from the 36
patients hospitalized in nine different wards. The macrorestric-
tion pattern of the isolates consisted of 22 discernible bands
ranging from 10 to 260 kbp (Fig. 2). Thirty-six isolates showed
very closely related patterns with one- or two-fragment varia-
tions. According to the report of Zarrilli et al. (22), the PFGE
analysis showed the presence of an epidemic clone and that the
OXA-23-producing isolates recovered from January to August
2003 were of a clonal origin.
DISCUSSION
Since 2003, a high degree of imipenem resistance incidence
has been observed among nosocomial A. baumannii isolates in
Korea. Therefore, it was our purpose to ascertain whether the
resistance was due to the dissemination of an imipenem resis-
tance determinant and/or to the spread of one A. baumannii
clone. Microbiological assays showed that imipenem was in-
activated by imipenem-resistant A. baumannii isolates. An al-
teration of carbapenemase activity was not observed in the
presence of EDTA, suggesting the production of a non-metal-
lo--lactamase. OXA class D carbapenemases have been iden-
tified in A. baumannii collected in UK (OXA-23) (6), Spain
(OXA-24, -25, and -40) (1, 3, 6, 7), Belgium (OXA-26) (18),
and Singapore (OXA-27) (18). A. baumannii is an emerg-
ing nosocomial pathogen that is in part due to the capacity of
acquiring resistance to multiple antimicrobial agents. Because
OXA-23-producing A. baumannii confers resistance to most
-lactams, such as imipenem, aztreonam, ceftazidime, and
cefepime, a limited number of antimicrobial agents maintain
reliable activity against OXA-23-producing A. baumannii, in-
cluding polymyxin, sulbactam, and minocycline (5). However,
our studies revealed that 78% of OXA-23-producing A. bau-
mannii isolates showed resistance to ampicillin-sulbactam.
Thus, it is important to monitor and control the spread of
OXA-23-producing A. baumannii conferring resistance to most
-lactams.
We detected 52 different isolates of imipenem-resistant
A. baumannii from Korean patients. Of 52 isolates, 36 pro-
duced OXA-23. The imipenem resistance of the remaining
isolates may be due to reduced permeability of the outer mem-
brane, alteration in penicillin biding proteins (18), and/or re-
cently reported OXA derivatives such as OXA-58 (GenBank
accession number AY570763). The clonal relatedness of A.
baumannii Korean isolates was evaluated by PFGE. All of the
isolates presented a very similar antibiotic resistance profile
and a very similar DNA fingerprinting pattern. Such a corre-
spondence of phenotypic and genotypic characteristics can be
explained by a common clonal origin. Our results indicate that
the observed imipenem resistance among 36 Korean A. bau-
mannii isolates is due to the spread of an OXA-23-producing
clone. Although a clonal outbreak due to an OXA-23-produc-
ing strain has been reported in Brazil (5), this is the first report
of an OXA-23-producing clone in Asia. The clinical signifi-
cance of these isolates, which were widespread in Korea, is of
great importance, since clinicians are advised against the use of
extended-spectrum cephalosporins, aztreonam, cephamycins,
imipenem, and aminoglycosides. This observation emphasizes
the importance of having effective control measures in Asian
hospitals, such as early detection of colonized patients, isola-
tion procedures, and a judicious use of antibiotics.
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